Rehabilitation Robots Market (2026-2036)
The global Rehabilitation Robots Market was valued at USD 1.18 billion in 2025. This market is expected to reach USD 6.82 billion by 2036 from an estimated USD 1.36 billion in 2026, registering a CAGR of 17.5% during the forecast period (2026-2036).
- Published
- Oct 2026
- Pages
- 315
- Format
- PDF + Excel
- Report ID
- MR-2238
- Base year
- 2025
- 2025 · BASELINE
- $1.18B
- 2036
- $6.82B
- CAGR 2026–2036
- 17.5%
2025 baseline · 2026–2036 forecast at 17.5% CAGR · hover a bar for the value
Key highlights
The global Rehabilitation Robots Market is projected to reach USD 6.82 billion by 2036, driven by the neurological and aging burden, reimbursement breakthroughs, and advances in robotics.
North America is expected to account for the largest market share in 2026, while Asia-Pacific is projected to register the fastest growth during the forecast period.
Medicare now pays for personal exoskeletons. In April 2024, the U.S. Centers for Medicare & Medicaid Services finalized a lump-sum Medicare payment for personal exoskeletons of USD 91,032, within a range of USD 81,929 to USD 109,238, after classifying them in the brace benefit category and determining that they incorporate revolutionary features not described by existing codes.
By product, Gait Training Robots are expected to account for the largest market share, whereas Wearable Powered Orthoses and Personal Exoskeletons are projected to witness the fastest growth through 2036.
Reimbursement is translating into sales. Myomo, maker of the MyoPro powered arm orthosis, reported fourth-quarter 2024 revenue of USD 12.1 million, up 154%, with 220 revenue units and its first positive quarterly cash flow after scaling to serve Medicare Part B patients, and Lifeward delivered 15 ReWalk personal exoskeletons in the third quarter of 2025 compared with four a year earlier, driven by Medicare-related sales.
Technology is advancing. The U.S. FDA cleared Wandercraft's self-balancing Atalante X exoskeleton in February 2024 for people with spinal cord injuries at levels T5 to L5, enabling users to stand and walk without crutches.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026-2036 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| CAGR (Value) | 17.5% |
| Format | PDF, Excel & Cloud Portal · 315 pages |
| Market Size (Value) in 2026 | USD 1.36 Billion |
| Market Size (Value) in 2036 | USD 6.82 Billion |
| Segments Covered | By Product: Gait Training Robots, Lower-Limb Exoskeletons, Upper-Limb Rehabilitation Robots, Wearable Powered Orthoses, Hand & Finger Rehabilitation Robots, Body-Weight Support & Balance Systems, Software & Tele-Rehabilitation. By Body Part: Lower Extremity, Upper Extremity, Full Body. By Care Setting: Clinical, Home & Personal. By Indication: Stroke, Spinal Cord Injury, Traumatic Brain Injury, Multiple Sclerosis, Cerebral Palsy, Orthopedic & Geriatric Conditions. By End User: Hospitals & Rehabilitation Centers, Outpatient & Physical Therapy Clinics, Home Care & Personal Users, Military & Veterans Healthcare, Research Institutions. |
| Countries Covered | North America: U.S., Canada. Europe: Germany, Switzerland, France, Italy, U.K., Austria, Rest of Europe. Asia-Pacific: Japan, China, South Korea, India, Australia, Rest of Asia-Pacific. Latin America: Brazil, Mexico, Rest of Latin America. Middle East & Africa: Israel, Saudi Arabia, UAE, South Africa, Rest of Middle East & Africa. |
| Key Companies | DIH (Hocoma, Motek), Lifeward (ReWalk, AlterG), Ekso Bionics, Myomo, Cyberdyne, Wandercraft, Tyromotion, Bionik Laboratories, Fourier Intelligence, Motorika, Harmonic Bionics, Barrett Medical, Toyota, and Angel Robotics. |
Report overview
Segments covered: product, body part, care setting, indication, end user.
The growth of this market is mainly driven by the rising burden of stroke, spinal cord injury, and age-related mobility impairment, reimbursement breakthroughs for personal exoskeletons and powered orthoses, and advances in robotics that enable self-balancing and more capable devices. However, the high cost of rehabilitation robots and limited reimbursement, mixed clinical evidence for some applications, the financial constraints of small specialized manufacturers, and device limitations that restrict eligible patient populations restrain the growth of this market.
Furthermore, home and personal-use exoskeletons, upper-limb wearable orthoses, and tele-rehabilitation and data-driven therapy are expected to offer growth opportunities for the stakeholders in this market. However, shortages of trained rehabilitation professionals, regulatory requirements for home and personal use, demonstrating long-term outcomes and cost-effectiveness, and a fragmented payer landscape across countries remain major challenges impacting the growth of this market. Additionally, the shift from clinical to home and personal use, the emergence of self-balancing hands-free exoskeletons, the integration of sensors, data, and AI into therapy, and the convergence of rehabilitation and humanoid robotics are prominent trends in this market.
The Rehabilitation Robots Market comprises robotic and powered devices used to restore, assist, or train movement in people with neurological, musculoskeletal, and age-related impairments. The market covers gait training robots, including treadmill-based and end-effector systems used in clinics; lower-limb exoskeletons for clinical rehabilitation and personal mobility; upper-limb rehabilitation robots for arm and shoulder therapy; wearable powered orthoses that amplify weak muscle signals; hand and finger rehabilitation robots; body-weight support, anti-gravity, and balance systems; and associated software, tele-rehabilitation, and services. Industrial exoskeletons for workers, prosthetics, and surgical robots are excluded. The ecosystem spans device manufacturers, rehabilitation hospitals and clinics, therapists, payers including Medicare, the U.S. Department of Veterans Affairs, and national insurers, regulators, and patients and caregivers.
The clinical need is large and growing. According to the World Stroke Organization, there are about 12 million new strokes each year and more than 100 million people living with the consequences of stroke, the World Health Organization estimates that more than 15 million people are living with spinal cord injury, and the WHO projects that one in six people worldwide will be aged 60 or older by 2030. The WHO has estimated that about 2.4 billion people worldwide live with a health condition that could benefit from rehabilitation, while health systems face shortages of therapists and other health workers.
Reimbursement is beginning to open the market for personal devices. In April 2024, the U.S. Centers for Medicare & Medicaid Services finalized a lump-sum Medicare payment of USD 91,032 for personal exoskeletons, after classifying them in the brace benefit category, and Myomo, whose MyoPro powered orthosis gained Medicare coverage, reported fourth-quarter 2024 revenue of USD 12.1 million, up 154%. The U.S. Veterans Health Administration has had a personal exoskeleton policy since 2015 covering about 9 million veterans, and Germany's statutory accident insurance, the DGUV, has covered personal exoskeletons for 80 million people since 2019. Lifeward delivered 15 ReWalk units in the third quarter of 2025, up from four a year earlier, driven by Medicare-related sales.
The market still faces significant constraints. Devices are expensive, clinical evidence varies by application, with a large randomized trial published in The Lancet in 2019 finding that robot-assisted arm training did not improve arm function more than usual care after stroke, and many manufacturers are small companies with limited capital; Lifeward reported that revenue from its AlterG anti-gravity products declined in the third quarter of 2025. At the same time, technology continues to improve, as shown by the FDA clearance of Wandercraft's self-balancing Atalante X exoskeleton in February 2024 and the growing use of sensors, software, and AI to personalize therapy.
Market dynamics
18 factors across 5 forcesRising Burden of Stroke, Spinal Cord Injury, and Age-Related Mobility Impairment
The rising burden of stroke, spinal cord injury, and age-related mobility impairment is a major factor driving the Rehabilitation Robots Market. According to the World Stroke Organization, about 12 million people have a stroke each year and more than 100 million people worldwide are living with its consequences, many with lasting weakness in the arms or legs, and the World Health Organization estimates that more than 15 million people are living with spinal cord injury. Population aging is increasing the number of people with mobility limitations, with the WHO projecting that one in six people worldwide will be aged 60 or older by 2030, and the WHO has estimated that about 2.4 billion people live with a health condition that could benefit from rehabilitation. Rehabilitation robots allow therapists to deliver more intensive, repetitive, and measurable therapy, which is associated with better recovery, making them an increasingly important tool as demand for rehabilitation outpaces the capacity of health systems.
Reimbursement Breakthroughs for Personal Devices
Reimbursement breakthroughs for personal exoskeletons and powered orthoses are significantly expanding the market. In April 2024, the U.S. Centers for Medicare & Medicaid Services finalized a lump-sum Medicare payment for personal exoskeletons of USD 91,032, within a range of USD 81,929 to USD 109,238, after classifying them in the brace benefit category, which Lifeward described as concluding all open items related to Medicare coverage, coding, and reimbursement. Myomo reported fourth-quarter 2024 revenue of USD 12.1 million, up 154%, with 220 revenue units and its first positive quarterly cash flow after scaling to serve Medicare Part B patients, and Lifeward delivered 15 ReWalk units in the third quarter of 2025 compared with four a year earlier, with a pipeline of more than 117 qualified leads in the U.S. These precedents, together with the Veterans Health Administration's personal exoskeleton policy covering about 9 million veterans since 2015 and Germany's DGUV coverage of 80 million people since 2019, are expected to encourage other payers to cover personal rehabilitation devices.
Advances in Robotics Enabling More Capable Devices
Advances in robotics, sensors, and control are enabling more capable and easier-to-use rehabilitation devices. In February 2024, the U.S. FDA cleared Wandercraft's Atalante X, a self-balancing exoskeleton that allows people with spinal cord injuries at levels T5 to L5 to stand and walk without crutches, freeing their hands and reducing the physical burden on therapists. Improvements in actuators, batteries, and lightweight materials are making exoskeletons and powered orthoses lighter and more comfortable, while sensors and software allow devices to adapt assistance in real time and record detailed data on patient performance. These advances expand the range of patients who can benefit and support use in both clinical and home settings. Manufacturing scale and design improvements are also improving economics: Lifeward's gross margin rose to 42.2% of revenue in the first quarter of 2025 from 26.4% a year earlier, and advances in humanoid robotics, such as NVIDIA's release in March 2025 of an open foundation model for humanoids demonstrated on Fourier's GR-1 robot, are expected to flow into rehabilitation devices.
Table of contents
13 chapters · 155 sections · 315 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Product | Gait Training Robots | Wearable Powered Orthoses |
| By Body Part | Lower Extremity | Upper Extremity |
| By Care Setting | — | Rapid growth of this |
| By Indication | Stroke | Orthopedic & Geriatric Conditions |
| By End User | Hospitals & Rehabilitation Centers | Home Care & Personal Users |
By Product
- The Gait Training Robots segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to the installed base of treadmill-based and end-effector systems in rehabilitation hospitals and supportive evidence for gait training after stroke.
- However, the Wearable Powered Orthoses segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to Medicare coverage and demand for devices that assist daily activities at home.
By Body Part
- The Lower Extremity segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to the importance of walking recovery and the adoption of gait trainers and exoskeletons.
- However, the Upper Extremity segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to growing reimbursement for wearable arm orthoses and the large population with persistent arm weakness after stroke.
By Care Setting
- The Clinical segment is expected to account for the larger share of the market.
- The large share of this segment is mainly due to hospital and rehabilitation center purchases of gait trainers and upper-limb systems.
- However, the Home & Personal segment is projected to register the higher CAGR during the forecast period.
- The rapid growth of this segment is attributed to Medicare's April 2024 payment for personal exoskeletons and growing coverage for powered orthoses.
By Indication
- The Stroke segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to the size of the stroke survivor population, with more than 100 million people living with the consequences of stroke.
- However, the Orthopedic & Geriatric Conditions segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to population aging and demand for mobility assistance among older adults.
By End User
- The Hospitals & Rehabilitation Centers segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to their role in acute and inpatient neurological rehabilitation.
- However, the Home Care & Personal Users segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to reimbursement for personal devices and the shift of rehabilitation to the community.
Geographic analysis
North America
Largest shareIn 2026, North America is expected to account for the largest share of the global Rehabilitation Robots Market. The region's dominance is supported by favorable reimbursement developments, a large rehabilitation infrastructure, and leading manufacturers. In April 2024, the U.S. Centers for Medicare & Medicaid Services finalized a lump-sum payment of USD 91,032 for personal exoskeletons, the Veterans Health Administration has had a personal exoskeleton policy covering about 9 million veterans since 2015, and Myomo's fourth-quarter 2024 revenue rose 154% to USD 12.1 million after scaling to serve Medicare Part B patients. The U.S. FDA cleared Wandercraft's self-balancing Atalante X in February 2024, and U.S.-based companies including Ekso Bionics, Myomo, and Lifeward, which is headquartered in the U.S. and Israel, are leading suppliers. Canada's rehabilitation hospitals are also adopting robotic therapy. North America
Europe
Europe is expected to account for a significant share of the market and is home to several leading manufacturers, including Switzerland's Hocoma, part of DIH, which developed the widely used Lokomat gait trainer, Austria's Tyromotion, and France's Wandercraft. Germany is a leading market, with the statutory accident insurance DGUV covering personal exoskeletons for 80 million people since 2019 and Lifeward reporting contractual coverage for 45% of Germans under statutory and private health insurance. Manufacturers must comply with the EU Medical Device Regulation, with transition periods extended to 2027 and 2028, and aging populations in Italy, Germany, and other countries are increasing demand for rehabilitation. Europe
Asia-Pacific
Fastest growthHowever, Asia-Pacific is projected to register the highest CAGR during the forecast period. The rapid growth of this region is attributed to rapidly aging populations, rising stroke incidence, and strong domestic robotics industries. Japan, where more than 29% of the population is aged 65 or older, is home to Cyberdyne, whose HAL exoskeleton received national health insurance coverage for certain neuromuscular diseases, and Toyota, which has developed the Welwalk gait training robot. China's Fourier Intelligence, which developed rehabilitation robots and the GR-1 humanoid used to demonstrate NVIDIA's GR00T N1 model in 2025, and other Chinese manufacturers are expanding production, while South Korea's Angel Robotics and companies in India and Australia are growing the regional supply base. Asia-Pacific
Latin America
Latin America is expected to account for a smaller share of the market, but demand is growing as populations age and stroke burden rises. Brazil and Mexico have large rehabilitation networks and private hospitals adopting robotic therapy, and with more than 100 million people living with the consequences of stroke worldwide, according to the World Stroke Organization, and the World Health Organization projecting that one in six people globally will be aged 60 or older by 2030, the need for rehabilitation in the region is increasing. Limited reimbursement for personal devices means adoption is concentrated in leading private and public rehabilitation centers. Latin America
Middle East & Africa
The Middle East & Africa is expected to register strong growth from a small base. Israel is a center of rehabilitation robotics innovation, as the birthplace of ReWalk, whose parent Lifeward operates from Yokneam, and of other rehabilitation technology companies, while Saudi Arabia and the UAE are investing in advanced rehabilitation centers as part of health system modernization, supported by high rates of diabetes and road traffic injuries that increase demand for neurological and mobility rehabilitation. South Africa's private hospitals are also adopting rehabilitation technologies. ReWalk, founded in Israel in 2001, received the first U.S. FDA clearance for a personal exoskeleton in 2014, and Lifeward, its parent, reported delivering 15 ReWalk units in the third quarter of 2025, reflecting the continuing role of Israeli technology in the global market. Middle East & Africa
Competitive landscape
The global Rehabilitation Robots Market is fragmented, with specialized rehabilitation robotics companies, medical technology groups, Japanese and Chinese robotics firms, and startups developing exoskeletons, gait trainers, upper-limb robots, and wearable orthoses. Competition centers on clinical evidence, regulatory clearances, reimbursement coverage, device usability and weight, therapist workflow, data and software capabilities, service and training, and price.
Leading companies are pursuing reimbursement coverage, expanding into home and personal use, developing self-balancing and lighter devices, adding software, data, and tele-rehabilitation capabilities, and consolidating product portfolios, as illustrated by Lifeward's combination of ReWalk exoskeletons with AlterG anti-gravity systems.
The report provides a comprehensive competitive assessment of the leading companies operating in the global Rehabilitation Robots Market. The key players profiled in the report include DIH Holding US, Inc. (Hocoma, Motek) (Switzerland/U.S.), Lifeward Ltd. (ReWalk, AlterG) (U.S./Israel), Ekso Bionics Holdings, Inc. (U.S.), Myomo, Inc. (U.S.), Cyberdyne Inc. (Japan), Wandercraft SAS (France), Tyromotion GmbH (Austria), Bionik Laboratories Corp. (U.S.), Fourier Intelligence (China), Motorika (Israel), Harmonic Bionics, Inc. (U.S.), Barrett Medical (U.S.), Toyota Motor Corporation (Japan), and Angel Robotics Co., Ltd. (South Korea).
- DIH (Hocoma, Motek)
- Lifeward (ReWalk, AlterG)
- Ekso Bionics
- Myomo
- Cyberdyne
- Wandercraft
- Tyromotion
- Bionik Laboratories
- Fourier Intelligence
- Motorika
- Harmonic Bionics
- Barrett Medical
- Toyota
- Angel Robotics
Expert perspectives
Rehabilitation robotics is moving from specialized clinical equipment toward mainstream care. The need is vast, with more than 100 million people living with the consequences of stroke and an aging global population, and reimbursement is finally catching up, as shown by Medicare's USD 91,032 payment for personal exoskeletons in April 2024 and Myomo's 154% revenue growth after gaining Medicare Part B access.
Three structural changes are expected to shape the market through 2036. First, rehabilitation will shift from clinics to homes as personal exoskeletons and wearable orthoses gain coverage. Second, devices will become lighter, self-balancing, and more intelligent, drawing on advances in humanoid robotics and AI. Third, evidence and data will determine reimbursement, favoring companies that can demonstrate functional outcomes and cost-effectiveness.
For companies planning entry or expansion, the most attractive positions over the forecast period are likely to be found in personal exoskeletons and wearable orthoses with reimbursement, self-balancing lower-limb systems, upper-limb assistive devices, tele-rehabilitation software, and emerging markets in Asia-Pacific. The principal risks are high costs, mixed evidence for some applications, the financial fragility of small manufacturers, and fragmented reimbursement.
Customer perspectives
Insights gathered during primary interviews with physiatrists, physical and occupational therapists, rehabilitation hospital administrators, and payer representatives highlight where purchasing priorities are shifting. The following perspectives reflect recurring themes raised across these discussions.
“This reflects the impact of reimbursement on personal exoskeleton adoption and the need for training.”
“This indicates the importance of clinical evidence in purchasing decisions.”
“This points to real-world outcomes evidence as the path to broader reimbursement.”
Frequently asked questions
The global Rehabilitation Robots Market is estimated at USD 1.36 billion in 2026.
Cite this report
Meticulous Research. (2026). Rehabilitation Robots Market - Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MR-2238). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/rehabilitation-robots-market-6921